Anupam Rasayan India Limited has reported Consolidated financial results for the period ended March 31, 2023. The company has posted net profit of Rs. 56.67 crores for the period ended March 31, 2023 as against net profit of Rs.46.10 crores for the period ended March 31, 2022.

Anupam Rasayan India has reported total income of Rs. 504.22 crores during the period ended March 31, 2023 as compared to Rs.316.85 crores during the period ended March 31, 2022.

For the Financial year ended March 31, 2023, Anupam Rasayan India has reported total income of Rs.1610.47 crores as compared to Rs.1081.10 crores during the Financial Year ended March 31, 2022.

The company has posted net profit of Rs.180.84 crores for the Financial Year ended March 31, 2023 as against net profit of Rs.152.179 crores for the Financial Year ended March 31, 2022.

Speaking on the performance, Anand Desai, Managing Director, Anupan Rasayan, said: "We have continued our growth momentum with a 49% YoY revenue growth on the back of new products commercialized during the year as well as steady growth of the organic portfolio.”

The company has continued its focus on adding more value-added products in our basket as well as bringing financial efficiencies. “We have already started witnessing the results of the same which is visible in stable margins and improved working capital resulting in strong cash generation of Rs. 244 crore,” Desai said and added that our strategic investments in infrastructure, people and technology have also started yielding great results which is visible in the growth that we have delivered as well as the new LOIs we have signed where majority of the customers are new clients.

The company further invests in strengthening and expanding these pillars of growth. “As we stand, we have signed contracts and LOIs of Rs. 5,483 crore giving us a strong revenue visibility for the coming years. At the same time, we are witnessing a robust traction in customer engagement as we remain in advance stage of discussions with customers across geographies for many niche and high value molecules. All these factors give us a reassurance of sustained robust growth in FY24,” he added.